- Astragaloside IV restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway
Jie Xi et al, 2023, BMC Pulmonary Medicine CrossRef - Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response
Cheng Li et al, 2022, Phytomedicine CrossRef - A Network Pharmacology Prediction and Molecular Docking-Based Strategy to Explore the Potential Pharmacological Mechanism of Astragalus membranaceus for Glioma
Yu Feng et al, 2023, International Journal of Molecular Sciences CrossRef - Natural Substances vs. Approved Drugs in the Treatment of Main Cardiovascular Disorders—Is There a Breakthrough?
Jelica Grujić-Milanović et al, 2023, Antioxidants CrossRef - Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective
Ran-ran Wang et al, 2022, Pharmacological Research CrossRef - Lung inflammation perturbation by engineered nanoparticles
Xiaofei Zhou et al, 2023, Frontiers in Bioengineering and Biotechnology CrossRef - Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets
Yongchao Zhao et al, 2023, Signal Transduction and Targeted Therapy CrossRef - Astragaloside IV in Hypoxic Pulmonary Hypertension: an In Vivo and In Vitro Experiments
null XinTian et al, 2022, Applied Biochemistry and Biotechnology CrossRef - Review on the protective mechanism of astragaloside IV against cardiovascular diseases
Chunkun Yang et al, 2023, Frontiers in Pharmacology CrossRef - Traditional Chinese medicine monomers: Targeting pulmonary artery smooth muscle cells proliferation to treat pulmonary hypertension
Xiuli Yang et al, 2023, Heliyon CrossRef - Inhibiting IL-6 in medicine: a new twist to sustain inhibition of his cytokine tin the therapy of Pulmonary Arterial Hypertension
Enrico Gugliandolo et al, 2023, Pharmacological Research CrossRef - Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling
Jinchun Wu et al, 2022, Cardiovascular Diabetology CrossRef - Effect of Qiling Jiaogulan Powder on Pulmonary Fibrosis and Pulmonary Arteriole Remodeling in Low-Temperature-Exposed Broilers
Juan Yu et al, 2022, Animals CrossRef - Matrine alleviates hypoxia‐induced inflammation and pulmonary vascular remodelling via RPS5/NF‐κB signalling pathway
Mingxing Li et al, 2024, Journal of Biochemical and Molecular Toxicology CrossRef - Natural Products for the Treatment of Pulmonary Hypertension: Mechanism, Progress, and Future Opportunities
Zuomei Zeng et al, 2023, Current Issues in Molecular Biology CrossRef - High-Throughput Phytochemical Unscrambling of Flowers Originating from Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) P. K. Hsiao and Astragalus membranaceus (Fisch.) Bug. by Applying the Intagretive Plant Metabolomics Method Using UHPLC−Q−TOF−MS/MS
Qi Liu et al, 2023, Molecules CrossRef - Insights into Endothelin Receptors in Pulmonary Hypertension
Ruiqi Liu et al, 2023, International Journal of Molecular Sciences CrossRef - Antihypertension effect of astragaloside IV during cerebral ischemia reperfusion in rats
Fengyan Shen et al, 2022, Molecular Medicine Reports CrossRef - Recent pharmacological advances in the treatment of cardiovascular events with Astragaloside IV
Zehui Xu et al, 2023, Biomedicine & Pharmacotherapy CrossRef - Recent advances in the potential effects of natural products from traditional Chinese medicine against respiratory diseases targeting ferroptosis
Tian Chen et al, 2024, Chinese Medicine CrossRef - Nobiletin attenuates monocrotaline-induced pulmonary arterial hypertension through PI3K/Akt/STAT3 pathway
Qin Yin et al, 2023, Journal of Pharmacy and Pharmacology CrossRef